• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

P2Y6 受体通过以依赖于 AP-1 的方式增加上皮细胞中 CXC 趋化因子配体 8 的表达,促进中性粒细胞募集到炎症性肠道黏膜。

P2Y6 receptor contributes to neutrophil recruitment to inflamed intestinal mucosa by increasing CXC chemokine ligand 8 expression in an AP-1-dependent manner in epithelial cells.

机构信息

Department of Anatomy and Cell Biology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada.

出版信息

Inflamm Bowel Dis. 2012 Aug;18(8):1456-69. doi: 10.1002/ibd.21931. Epub 2011 Nov 17.

DOI:10.1002/ibd.21931
PMID:22095787
Abstract

BACKGROUND

Inflammatory bowel diseases are characterized by the presence of CXCL8 at the site of lesions resulting in neutrophil recruitment and loss of tissue functions. We report that P2Y(6) receptor activation stimulates CXCL8 expression and release by intestinal epithelial cells (IECs). In this context, we investigated if uridine 5'-diphosphate (UDP) enemas stimulate neutrophil recruitment to the mucosa of mice suffering from colitis-like disease and we characterized the signaling events linking P2Y(6) to CXCL8 expression in IEC.

METHODS

Neutrophil recruitment was monitored by immunofluorescence and FACS analysis. Expression of Cxcl1, a mouse functional homolog of CXCL8, was determined by quantitative real-time polymerase chain reaction (qPCR). Pharmacological inhibitors and interfering RNAs were used to characterize the signaling pathway. The outcomes of these treatments on protein phosphorylation and on CXCL8 expression were characterized by western blots, qPCR, luciferase, and chromatin immunoprecipitation (ChIP) assays.

RESULTS

Mutation of the AP-1 site in the CXCL8 core promoter abolished the UDP-stimulating effect. The c-fos/c-jun dimer was identified as the AP-1 complex regulating CXCL8 in response to UDP stimulation. Regulation of CXCL8 expression by P2Y(6) required PKCδ activation upstream of the signaling pathway composed of MEK1/2-ERK1/2 and c-fos. UDP administration to mice suffering from colitis-like disease increased the number of neutrophil infiltrating the mucosa, correlating with Cxcl1 increased expression in IEC and the severity of inflammation.

CONCLUSIONS

This study not only describes the P2Y(6) signaling mechanism regulating CXCL8 expression in IEC, but it also illustrates the potential of targeting P2Y(6) to reduce intestinal inflammation.

摘要

背景

炎症性肠病的特征是病变部位存在 CXCL8,导致中性粒细胞募集和组织功能丧失。我们报告说,P2Y(6) 受体的激活刺激肠上皮细胞 (IEC) 表达和释放 CXCL8。在这种情况下,我们研究了尿苷 5'-二磷酸 (UDP) 灌肠是否会刺激患有类似结肠炎疾病的小鼠的黏膜中性粒细胞募集,并且我们描述了将 P2Y(6) 与 IEC 中 CXCL8 表达联系起来的信号事件。

方法

通过免疫荧光和 FACS 分析监测中性粒细胞募集。通过定量实时聚合酶链反应 (qPCR) 确定 Cxcl1(CXCL8 的小鼠功能同源物)的表达。使用药理学抑制剂和干扰 RNA 来描述信号通路。这些治疗方法对蛋白磷酸化和 CXCL8 表达的影响通过 Western blot、qPCR、荧光素酶和染色质免疫沉淀 (ChIP) 分析进行了表征。

结果

在 CXCL8 核心启动子中的 AP-1 位点发生突变后,UDP 的刺激作用被消除。c-fos/c-jun 二聚体被鉴定为响应 UDP 刺激调节 CXCL8 的 AP-1 复合物。P2Y(6) 对 CXCL8 表达的调节需要 PKCδ 在由 MEK1/2-ERK1/2 和 c-fos 组成的信号通路的上游激活。UDP 给药于患有类似结肠炎疾病的小鼠可增加浸润黏膜的中性粒细胞数量,这与 IEC 中 Cxcl1 表达增加和炎症的严重程度相关。

结论

这项研究不仅描述了调节 IEC 中 CXCL8 表达的 P2Y(6) 信号机制,而且还说明了靶向 P2Y(6) 以减少肠道炎症的潜力。

相似文献

1
P2Y6 receptor contributes to neutrophil recruitment to inflamed intestinal mucosa by increasing CXC chemokine ligand 8 expression in an AP-1-dependent manner in epithelial cells.P2Y6 受体通过以依赖于 AP-1 的方式增加上皮细胞中 CXC 趋化因子配体 8 的表达,促进中性粒细胞募集到炎症性肠道黏膜。
Inflamm Bowel Dis. 2012 Aug;18(8):1456-69. doi: 10.1002/ibd.21931. Epub 2011 Nov 17.
2
Intestinal inflammation increases the expression of the P2Y6 receptor on epithelial cells and the release of CXC chemokine ligand 8 by UDP.肠道炎症会增加上皮细胞上P2Y6受体的表达以及UDP诱导的CXC趋化因子配体8的释放。
J Immunol. 2008 Feb 15;180(4):2659-68. doi: 10.4049/jimmunol.180.4.2659.
3
Amplification loop of the inflammatory process is induced by P2X7R activation in intestinal epithelial cells in response to neutrophil transepithelial migration.炎症过程的扩增环是由 P2X7R 激活诱导的,这种激活发生在响应中性粒细胞跨上皮迁移的肠道上皮细胞中。
Am J Physiol Gastrointest Liver Physiol. 2010 Jul;299(1):G32-42. doi: 10.1152/ajpgi.00282.2009. Epub 2010 Feb 25.
4
Increased Expression of Interleukin-36, a Member of the Interleukin-1 Cytokine Family, in Inflammatory Bowel Disease.白细胞介素-1细胞因子家族成员白细胞介素-36在炎症性肠病中的表达增加。
Inflamm Bowel Dis. 2016 Feb;22(2):303-14. doi: 10.1097/MIB.0000000000000654.
5
Duox1-derived H2O2 modulates Cxcl8 expression and neutrophil recruitment via JNK/c-JUN/AP-1 signaling and chromatin modifications.由Duox1产生的过氧化氢通过JNK/c-JUN/AP-1信号传导和染色质修饰来调节Cxcl8表达和中性粒细胞募集。
J Immunol. 2015 Feb 15;194(4):1523-33. doi: 10.4049/jimmunol.1402386. Epub 2015 Jan 12.
6
Interleukin-10 blocked endoplasmic reticulum stress in intestinal epithelial cells: impact on chronic inflammation.白细胞介素-10可阻断肠上皮细胞的内质网应激:对慢性炎症的影响。
Gastroenterology. 2007 Jan;132(1):190-207. doi: 10.1053/j.gastro.2006.10.030. Epub 2006 Oct 21.
7
Functional expression of the P2Y14 receptor in human neutrophils.P2Y14受体在人中性粒细胞中的功能表达。
Eur J Pharmacol. 2006 Aug 14;543(1-3):166-73. doi: 10.1016/j.ejphar.2006.05.037. Epub 2006 Jun 7.
8
Effects of transcription factor activator protein-1 on interleukin-8 expression and enteritis in response to Clostridium difficile toxin A.转录因子激活蛋白-1对艰难梭菌毒素A诱导的白细胞介素-8表达及肠炎的影响
J Mol Med (Berl). 2007 Dec;85(12):1393-404. doi: 10.1007/s00109-007-0237-7. Epub 2007 Jul 18.
9
Exacerbated intestinal inflammation in P2Y deficient mice is associated with Th17 activation.P2Y 缺陷小鼠的肠道炎症加重与 Th17 激活有关。
Biochim Biophys Acta Mol Basis Dis. 2019 Oct 1;1865(10):2595-2605. doi: 10.1016/j.bbadis.2019.06.019. Epub 2019 Jul 2.
10
The P2Y14 receptor of airway epithelial cells: coupling to intracellular Ca2+ and IL-8 secretion.气道上皮细胞的P2Y14受体:与细胞内Ca2+及白细胞介素-8分泌的偶联
Am J Respir Cell Mol Biol. 2005 Dec;33(6):601-9. doi: 10.1165/rcmb.2005-0181OC. Epub 2005 Aug 18.

引用本文的文献

1
Microglial P2Y calcium signaling promotes phagocytosis and shapes neuroimmune responses in epileptogenesis.小胶质细胞 P2Y 钙信号促进吞噬作用,并在癫痫发生中塑造神经免疫反应。
Neuron. 2024 Jun 19;112(12):1959-1977.e10. doi: 10.1016/j.neuron.2024.03.017. Epub 2024 Apr 12.
2
PGF facilitates pathological retinal angiogenesis by modulating endothelial FOS-driven ELR CXC chemokine expression.PGF 通过调节内皮细胞 FOS 驱动的 ELR CXC 趋化因子表达促进病理性视网膜血管生成。
EMBO Mol Med. 2023 Jan 11;15(1):e16373. doi: 10.15252/emmm.202216373. Epub 2022 Dec 13.
3
Physiologic roles of P2 receptors in leukocytes.
P2 受体在白细胞中的生理作用。
J Leukoc Biol. 2022 Nov;112(5):983-1012. doi: 10.1002/JLB.2RU0421-226RR. Epub 2022 Jul 15.
4
A novel definition and treatment of hyperinflammation in COVID-19 based on purinergic signalling.基于嘌呤能信号转导的新型 COVID-19 过度炎症反应定义和治疗方法。
Purinergic Signal. 2022 Mar;18(1):13-59. doi: 10.1007/s11302-021-09814-6. Epub 2021 Nov 10.
5
Hyperinflammation and airway surface liquid dehydration in cystic fibrosis: purinergic system as therapeutic target.囊性纤维化中的过度炎症和气道表面液体脱水:嘌呤能系统作为治疗靶点。
Inflamm Res. 2021 Jun;70(6):633-649. doi: 10.1007/s00011-021-01464-z. Epub 2021 Apr 27.
6
Targeting UDP-glucose pyrophosphorylase (UGPase): in vitro validation of a putative inhibitor.靶向尿苷二磷酸葡萄糖焦磷酸化酶(UGPase):一种假定抑制剂的体外验证
Drug Target Insights. 2020 Oct 7;14:26-33. doi: 10.33393/dti.2020.2103. eCollection 2020.
7
Control of Gut Inflammation by Modulation of Purinergic Signaling.嘌呤能信号转导调控肠道炎症
Front Immunol. 2020 Sep 25;11:1882. doi: 10.3389/fimmu.2020.01882. eCollection 2020.
8
The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases.嘌呤能系统作为治疗免疫介导的炎症性疾病的药理学靶点。
Pharmacol Rev. 2019 Jul;71(3):345-382. doi: 10.1124/pr.117.014878.
9
Nanoparticulate Drug Delivery Systems Targeting Inflammation for Treatment of Inflammatory Bowel Disease.用于治疗炎症性肠病的靶向炎症的纳米颗粒药物递送系统。
Nano Today. 2017 Oct;16:82-96. doi: 10.1016/j.nantod.2017.08.006. Epub 2017 Oct 9.
10
Purinergic Ligands as Potential Therapeutic Tools for the Treatment of Inflammation-Related Intestinal Diseases.嘌呤能配体作为治疗炎症相关肠道疾病的潜在治疗工具。
Front Pharmacol. 2018 Mar 14;9:212. doi: 10.3389/fphar.2018.00212. eCollection 2018.